US EditionPublished • loading... • Updated
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
- Zamto-Cel showed significant superiority over chemoimmunotherapy in transplant-ineligible patients at high risk of rapid disease progression, according to the primary analysis of the DALY 2-EU trial.
- Zamto-Cel improved event-free survival while maintaining a favorable tolerability profile in a high-risk population.
- Zamto-Cel is recognized as the first tandem CD20-CD19 non-cryopreserved CAR-T cell therapy, demonstrating meaningful clinical benefits with promising efficacy and safety.
- The primary endpoint of the trial was event-free survival, assessed by a blinded independent review committee, defined as the time to disease progression or death.
Insights by Ground AI
10 Articles
10 Articles
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time of 14-16 d…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources10
Leaning Left3Leaning Right2Center2Last UpdatedBias Distribution43% Left
Bias Distribution
- 43% of the sources lean Left
43% Left
L 43%
C 29%
R 28%
Factuality
To view factuality data please Upgrade to Premium
